Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
7 CRISPR Stocks With the Best Long-Term Potential
07:10pm, Monday, 30'th Jan 2023
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
04:40pm, Thursday, 01'st Dec 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis S.A. (CLLS) Q3 2022 Earnings Call Transcript
02:29pm, Friday, 04'th Nov 2022
Cellectis S.A. (NASDAQ:CLLS ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Mark Frat
Cellectis to Report Third Quarter 2022 Financial Results
04:37pm, Thursday, 27'th Oct 2022
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
08:23pm, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
Cellectis nomme Mark Frattini, M.D., Ph.D., en tant que directeur médical
08:21pm, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
NEW YORK, 28 sept. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gén
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
07:43am, Monday, 26'th Sep 2022 Benzinga
Gainers
Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares climbed 46.4% to close at $0.3750 on Friday.
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
04:16pm, Friday, 23'rd Sep 2022 Benzinga
Gainers
Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day ex
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket
11:16am, Friday, 23'rd Sep 2022 Benzinga
Gainers
HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading.
Rubius Therapeutics, Inc. (NASDAQ: RUBY) rose 32% to $0.60 in pre-market trading after declining 7% o
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:30pm, Monday, 19'th Sep 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Monthly information on share capital and company voting rights
08:30pm, Monday, 19'th Sep 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis annonce sa participation à quatre conférences investisseurs en septembre
08:56pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
NEW YORK, 01 sept. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gén
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
08:44pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platfor
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
04:44pm, Thursday, 01'st Sep 2022
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
